1313725-88-0

Basic information

• Product Name: Volitinib
• Synonyms: AZD6094,Volitinib, HMPL-504, Savolitinib;1-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazolo[4,5-b]pyrazine;(S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine;Volitinib;Savolitinib;HMPL-504(AZD6094, Volitinib);EOS-60799;AZD-6094)
• CAS NO: 1313725-88-0
• Molecular Formula: C17H15N9
• Molecular Weight: 345.3613
• Product Categories: API
• Mol File: 1313725-88-0.mol

Chemical Properties

• Appearance: /
• Density: 1.55±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 5.67±0.50(Predicted)
• CAS DataBase Reference: Volitinib(CAS DataBase Reference)
• NIST Chemistry Reference: Volitinib(1313725-88-0)
• EPA Substance Registry System: Volitinib(1313725-88-0)

Safety Data

• Hazardous Substances Data: 1313725-88-0(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
Volitinib is used as an anti-cancer agent for the treatment of cMet-dysregulated gastric cancer. It inhibits the c-Met receptor, which is often overactivated in various cancers, leading to the inhibition of tumor growth and progression.
Used in Drug Development:
Volitinib is used as a research compound for the development of new cancer therapies targeting the c-Met pathway. Its high selectivity and potent inhibitory activity make it a valuable tool for studying the role of c-Met in cancer and for developing new drugs to target this pathway.

Upstream product

• 1313723-58-8 1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine 
• 1270475-03-0 1-(imidazo[1,2-a]pyridin-6-yl)ethanamine 
• 36052-24-1 methyl 6-aminonicotinoate 
• 136117-69-6 methyl 6-imidazo<1,2-a>pyridinecarboxylate 
• 1313726-20-3 imidazo[1,2-a]pyridine-6-carboxylic acid methoxy(methyl)amide 
• 944905-12-8 1-(imidazo[1,2-a]pyridin-6-yl)ethanone 
• 1259603-82-1 (1S)-1-imidazo[1,2-a]pyridin-6-ylethanamine 
• 761446-44-0 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 139022-25-6 imidazo[1,2-a]pyridine-6-carboxylic acid 
• 3167-49-5 6-aminonicotinic acid 

Relevant articles and documents

Process Design and Optimization in the Pharmaceutical Industry: A Suzuki-Miyaura Procedure for the Synthesis of Savolitinib

A multidisciplinary approach covering synthetic, physical, and analytical chemistry, high-throughput experimentation and experimental design, process engineering, and solid-state chemistry is used to develop a large-scale (kilomole) Suzuki-Miyaura process. Working against clear criteria and targets, a full process investigation and optimization package is described highlighting how and why key decisions are made in the development of large-scale pharmaceutical processes.

PROCESS FOR PREPARATION OF SAVOLITINIB AND ITS INTERMEDIATES

The present application relates to a process for preparation of chiral amine fragment (IV) of savolitinib. The present application also relates to a process for preparation of savolitinib using the chiral amine (IV), as prepared by the process of the present application. The present application also discloses new intermediates useful for the synthesis of savolitinib. The present application further relates to crystalline forms of savolitinib, namely AA1, formic acid solvate and AA2. The present application also relates to amorphous solid dispersion of savolitinib.

IMPROVED METHOD FOR THE MANUFACTURE OF 3-[(1S)-1-IMIDAZO[1,2-A]PYRIDIN-6-YLETHYL]-5-(1-METHYLPYRAZOL-4-YL)TRIAZOLO[4,5-B]PYRAZINE AND POLYMORPHIC FORMS THEREOF

This specification generally relates to an improved method for the manufacture of 3-[(lS)-l -imidazo[ 1,2-a]pyridin-6-ylethyl]-5-(l-methylpyrazol-4-yl)triazolo[4,5- bjpyrazine (I), or pharmaceutically acceptable salts thereof; polymorphic forms thereof; and intermediates useful in the manufacture of such compounds and salts thereof. Formula (I).

Discovery of (S)-1-(1-(Imidazo[1,2- a ]pyridin-6-yl)ethyl)-6-(1-methyl-1 H -pyrazol-4-yl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal-Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine c-Met inhibitors. The structure-activity relationship of these compounds was investigated, leading to the identification of compound 28, which demonstrated favorable pharmacokinetic properties in mice and good antitumor activities in the human glioma xenograft model in athymic nude mice.

CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR

Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.